The Drug Discovery Toxicology Specialty Section (DDTSS)
DDTSS is hosting a webinar entitled “Species-specific urothelial toxicity with an anti-HIV noncatalytic site integrase inhibitor (NCINI) is related to unusual pH-dependent physicochemical changes” to present the work that was published in Toxicological Sciences and received the DDTSS “Paper of the Year” Award in 2022.
Professor Ruth Roberts won the DDTSS Paper of the Year Award this year and was presented with the award at the Society of Toxicology Annual Meeting in March.
Roberts RA, Campbell RA, Sikakana P, Sadler C, Osier M, Xu Y, Feng JY, Mitchell M, Sakowicz R, Chester A, Paoli E, Wang J, Burns-Naas LA. Species-Specific Urothelial Toxicity with an Anti-HIV Noncatalytic Site Integrase Inhibitor (NCINI) is Related to Unusual pH-Dependent Physicochemical Changes. Toxicol Sci. 2021 Aug 30;183(1):105-116. doi: 10.1093/toxsci/kfab073. PMID: 34117767. Download the free access paper here.
The webinar will take place next Friday May 13th at 10 – 11am PT | 12 – 1 pm CT | 1 – 2pm ET | 6-7pm BST.
This exciting talk will be followed by a brief question and answer session.
The session will be moderated by Dr Kai Connie Wu and Dr Satoko Kakiuchi-Kiyota
The Lead Author and Presenter
Professor Ruth A Roberts is Chair and Director of Drug Discovery at Birmingham University, UK and Cofounder of ApconiX, an integrated toxicology and ion channel company. Before that, Dr. Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of Toxicology for Aventis in Paris, France. Dr. Roberts was the recipient of the SOT Achievement award in 2002, the SOT Founders award in 2018 and the ATS ‘Millie’ award in 2022 and has >150 publications in peer reviewed journals.
The Co-Author and Co-Presenter
Dr. Leigh Ann Burns-Naas is an independent consultant and President of Magnolia Toxicology Consulting where she provides advice in the areas of nonclinical safety and strategic planning for drug development, as well as technical due diligence for in-licensing of business development opportunities. Prior to launching her company, Leigh Ann was Vice President and Head of Nonclinical Safety & Pathobiology at Gilead Sciences and before that she was a Drug Safety Therapeutic Area Leader for infectious disease and then oncology at Pfizer.